Startups & Business News
The world of pharmaceutical innovation just took a giant leap—literally—beyond Earth’s boundaries. Varda Space Industries has secured a staggering $187 million in Series C funding, a move that’s set to accelerate the development of drugs manufactured in the unique environment of space. This investment, led by Natural Capital and Shrug Capital with support from notable names like Peter Thiel and Founders Fund, brings Varda’s total capital raised to $329 million.
Why manufacture drugs in space?
The answer lies in the microgravity environment of low Earth orbit. On Earth, gravity can cause crystallization defects in drugs—especially complex biologics like monoclonal antibodies—impacting their bioavailability and effectiveness. In space, however, molecules float freely, enabling the formation of uniform crystals that can stabilize otherwise unstable drug forms and potentially enhance their therapeutic value.
Varda’s journey isn’t just theoretical
In 2023, the company’s W-1 mission successfully grew crystals of the anti-HIV drug ritonavir in orbit and returned them to Earth with their structure intact—a feat that had eluded researchers in terrestrial labs. This proof-of-concept demonstrated that space-based drug manufacturing could unlock new forms of medicines that are more effective and stable.
With the new funding, Varda is scaling up its operations.
The company has expanded its laboratory footprint in El Segundo, California, opening a 10,000-square-foot facility dedicated to advancing the crystallization of biologics and other pharmaceuticals. This lab will allow Varda’s team of structural biologists and crystallization experts to identify the most promising drug candidates for space-based production and refine the processes required for orbital manufacturing.
Varda isn’t stopping at drug development
Its orbital laboratories—the first of their kind outside the International Space Station—are also serving as hypersonic testbeds for government partners, including the U.S. Air Force and NASA, to test new technologies under real-world reentry conditions.
As the company prepares for additional missions—having already completed three successful launch-and-return operations with more on the horizon—Varda’s vision is clear: to make space the next frontier for pharmaceutical manufacturing, solving some of the industry’s toughest challenges and opening the door to life-changing medicines that would be impossible to create on Earth
Key Highlights
$187 Million Series C Funding:
Varda Space Industries has closed a major funding round, bringing its total capital raised to $329 million.Microgravity-Driven Innovation:
The company leverages the unique environment of space to develop pharmaceuticals with improved bioavailability and stability.Successful Space Mission:
Varda’s W-1 mission grew and returned high-quality crystals of the anti-HIV drug ritonavir, proving the viability of space-based drug manufacturing.Expansion of R&D Facilities:
Varda has launched a new 10,000-square-foot laboratory in El Segundo, California, dedicated to advancing space-enabled pharmaceutical research.Strategic Partnerships:
The funding round included support from leading investors and will help Varda collaborate with government agencies like NASA and the U.S. Air Force.Pioneering Orbital Labs:
Varda operates the first commercial orbital laboratories outside the ISS, supporting both pharmaceutical and hypersonic technology research.Future Missions Planned:
With three successful missions completed, Varda is preparing for additional launches to further expand its space-based drug development capabilities.
These highlights underscore Varda Space’s role in redefining the future of pharmaceutical innovation by harnessing the power of space.
futureTEKnow
Editorial Team
futureTEKnow is a leading source for Technology, Startups, and Business News, spotlighting the most innovative companies and breakthrough trends in emerging tech sectors like Artificial Intelligence (AI), Robotics, and the Space Industry.
Discover the companies and startups shaping tomorrow — explore the future of technology today.
Trending Companies
Latest Articles
Loop’s AI supply chain platform raises $95M Series C to predict disruptions before they hit
Loop just raised a $95M Series C to expand its AI-native supply chain platform, turning messy logistics data into early
London AI startup Lua wants to give every business its own AI workforce with $5.8M seed round
Linkedin X-twitter-square Facebook-square Startups & Business News AI agents are finally moving from demos to the day-to-day stack of real
Factory.ai raises $150M Series C to build fully autonomous software engineering “factories”
Factory has raised a $150M Series C at a $1.5B valuation to scale its autonomous “Droids” platform, betting that enterprises
Solidroad’s $25M bet on AI quality assurance for customer support
Solidroad has raised $25 million to bring AI-native quality assurance to every human and AI-powered customer interaction. The new funding
Turion Space’s $75M Series B bets on space domain awareness as the next defense infrastructure
Turion Space has raised more than $75 million in Series B funding to scale its Starfire platform and satellite fleet,
Mintlify’s $45M Series B Bet: Turning Documentation Into AI Infrastructure
Mintlify just raised a $45M Series B led by a16z and Salesforce Ventures to turn software documentation into core AI
nEye.ai’s $80M bet on optical circuit switching for AI data centers
nEye.ai has raised an $80 million Series C to scale optical circuit switching for AI data centers. This feature unpacks
Bluefish’s $43M Agentic Marketing Bet: How Fortune 500 Brands Are Fighting for AI Shelf Space
Bluefish has raised a $43 million Series B to expand its agentic marketing platform, giving Fortune 500 brands new tools
Anvil Robotics’ Physical AI Platform Targets Modular Robotics Infrastructure Bottleneck
Anvil Robotics is building a physical AI modular robotics platform that replaces fragmented, bespoke stacks with composable hardware, software, and
Sona’s $45M Series B bets that AI can finally fix frontline workforce software
London-based Sona has raised a $45M Series B to turn its AI-native workforce platform into core infrastructure for frontline enterprises,
Noon’s $44M AI-native product design platform aims to erase the gap between design and code
San Francisco-based Noon has raised $44M to build an AI-native product design platform that sits directly on live code, promising
AI financial newsroom startup FNS raises €1.5M — and tests how far regulators will let “no‑journalist” markets go
Copenhagen-based Financial News Systems has raised €1.5M to build a fully AI-driven financial newsroom with no journalists in the loop.
futureTEKnow is focused on identifying and promoting creators, disruptors and innovators, and serving as a vital resource for those interested in the latest advancements in technology.
© 2026 All Rights Reserved.